Prestige Consumer Healthcare Inc. Common Stock (PBH)

FairStock Score: 53/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable brands, honest balance sheets, and a price that leaves room for error. Prestige Consumer Healthcare sells OTC health and personal-care brands like BC, Goody's, and Boudreaux's Butt Paste, so it has some consumer familiarity and shelf presence. But the numbers are mixed. In fiscal Q1 2027, the quarter ended 2026-06-30, revenue was $265.7 million, net income was $29.2 million, and diluted EPS was $0.61. That revenue rose from $249.5 million in fiscal Q1 2026, but net income fell from $47.5 million, so profitability is under pressure. For fiscal year 2026, period ended 2026-03-31, revenue was $1.1 billion, net income was $190.3 million, and diluted EPS was $3.91, down from $214.6 million and $4.29 in fiscal year 2025. FairStock calculations as of the 2026-10-13 close show a P/E of 13.59, P/B of 1.20, ROE of 9.12%, ROCE of 4.58%, and a 10.2% trailing FCF yield. The free cash flow is attractive, and the Graham Number of $57.01 gives about 14.93% margin of safety. But the Piotroski F-Score is only 3/9, Altman Z-Score is 1.25, and debt-to-equity is 1.08, evidence of financial fragility. The stock is near the low end of its 52-week range, and FairStock classifies it as a TURNAROUND. With flat-to-declining revenue, falling profits, and low returns on capital, this is not a clear compounder. It looks statistically cheap on cash flow and book value, but the business quality and balance sheet demand skepticism.

In plain English: Prestige Consumer Healthcare sells over-the-counter health and personal care products, such as pain relievers and diaper rash creams. The company still makes money and produces a lot of cash, but sales and profits have weakened recently and it has a fair amount of debt. At $48.50, the shares look somewhat cheap compared with the company's cash flow and book value, but the weak trends mean the low price alone is not a clear signal.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-06-30) · fiscal Q3 2026 10-Q (period ended 2025-12-31) · fiscal Q2 2026 10-Q (period ended 2025-09-30) · fiscal Q1 2026 10-Q (period ended 2025-06-30) · FY2026 10-K (period ended 2026-03-31) · FY2025 10-K (period ended 2025-03-31) · FY2024 10-K (period ended 2024-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer